Management of Hematologic Disorders

  • Author: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Use of either recombinant human growth factor filgrastim[Hermans 1996] or sargramostim[Lieschke 1992] increases neutrophil counts in dose-dependent manner via different mechanisms
  • Pegfilgrastim, routinely used in some cancer settings, has potential to simplify management of neutropenia by allowing less frequent dosing[Lyman 2005]
  • ASCO issued guidelines for managing cancer patients with neutropenia, including preventing infection, that are useful for identifying patients who require hospitalization (Management Guidelines)[Flowers 2013]

Action required